{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:14:47Z","timestamp":1778368487319,"version":"3.51.4"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"0506","license":[{"start":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T00:00:00Z","timestamp":1327795200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>The goal of this study was to observe the therapeutic efficacy  of cyclophosphamide, vincristine and prednisone combined chemotherapy (COP) in  treating adult haemophagocytic lymphohistiocytosis (HLH). Fifteen cases  diagnosed with HLH were enrolled in our study. Each of them was treated with  the COP regimen. Two of the fifteen patients had autoimmune disease-associated  HLH (13.3%), 2\/15 had lymphoma-associated HLH (13.3%), 7\/15 had infection-associated  HLH (IAHLH) (46.7%), and the remaining 4\/15\u00a0developed the disease in the  absence of apparent underlying disease (26.7%). A complete response (CR) was  achieved in 7\/15 patients (46.7%), while a partial response (PR) was achieved in  5\/15 patients (33.3%). With a mean follow-up of 72.5 weeks, the one-year  overall survival was 66.7%. HLH of varying aetiology exhibited differing sensitivity  and response to the COP regimen. In combination with aetiological and  supportive treatment, the COP regimen as a mild and cost-effective chemotherapy  is especially favourable for IAHLH, autoimmune disease-associated HLH, and  disease severity precluding intensive treatment.<\/jats:p>","DOI":"10.4414\/smw.2012.13512","type":"journal-article","created":{"date-parts":[[2012,2,20]],"date-time":"2012-02-20T01:27:03Z","timestamp":1329701223000},"page":"w13512","source":"Crossref","is-referenced-by-count":4,"title":["Treatment  of haemophagocytic lymphohistiocytosis with cyclophosphamide, vincristine and  prednisone"],"prefix":"10.57187","volume":"142","author":[{"given":"Yixin","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2012,1,29]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1420\/1724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1420\/1725","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1420\/1724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:28:18Z","timestamp":1755228498000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,29]]},"references-count":0,"journal-issue":{"issue":"0506","published-online":{"date-parts":[[2012,1,30]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2012.13512","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,29]]}}}